Gene characteristics and efficacy of vaccination against infectious bronchitis virus field isolates from the United States and Israel (1996 to 2000)
Gene characteristics and efficacy of vaccination against infectious bronchitis virus field isolates from the United States and Israel (1996 to 2000)
复制标题
DOI：
10.1080/03079450500096539
复制
发表时间：
2005-06-01
期刊：
影响因子：
2.8
通讯作者：
Meir, R
中科院分区：
文献类型：
--
作者：
Gelb, J;Weisman, Y;Meir, R
采用逆转录-聚合酶链式反应、限制性片段长度多态性和测序技术，对美国和以色列商品鸡源的鸡传染性支气管炎病毒S I基因进行了研究。以Beauderte菌株为基础，使用跨越S1氨基末端区域的第48至219个氨基酸残基的部分序列进行分析。使用系统发育聚类和高序列同一性值来鉴定似乎来自这两个国家使用的IBV活疫苗的分离株。经S I测序和限制性内切酶片段长度多态性分析，发现与参考株和疫苗株无亲缘关系的新变异株。根据S I序列与现有疫苗的同源性，评估了疫苗接种控制传染性支气管炎病毒感染的可能性。用商业活毒株马萨诸塞州(麻萨诸塞州)、阿肯色州(阿肯色州)或DE/072/92接种通常对与疫苗相关的现场分离株产生免疫力，这些分离株与各自的疫苗株具有很高的SI序列相似性(>；=90%)。用含有MASS和ARK毒株的双价疫苗免疫提供了良好的交叉保护，与来自美国的5个变异株的氨基酸同源性分别为MASS的62%到69%和ARK的68%到83%，平均对攻击的抵抗率为81%。相比之下，H120疫苗株对来自以色列的氨基酸同一性从65%到67%的变异野毒株诱导了低水平的保护，从25%到58%不等。
The S I genes of isolates of avian coronavirus infectious bronchitis virus (IBV) from commercial chickens in the US and Israel (20 isolates from each country) were studied using reverse transcription-polymerase chain reaction restriction fragment length polymorphism and sequencing. Partial sequences spanning the amino terminus region of S1 from amino acid residues 48 to 219, based on the Beaudette strain, were used for analysis. Phylogenetic clustering and high-sequence identity values were used to identify isolates that appeared to be derived from live IBV vaccines used in the two countries. Novel variant strains, unrelated by S I sequencing and restriction fragment length polymorphism analyses to reference and vaccine strains, were also identified. Based on S I sequence identity to available vaccines, the potential to use vaccination to control IBV infections was evaluated. Vaccination with commercial live strains Massachusetts (Mass), Arkansas (Ark) or DE/072/92, generally produced immunity against vaccine-related field isolates displaying high SI sequence similarities (>= 90%) to the respective vaccine strains. Immunization with a bivalent vaccine containing the Mass and Ark strains provided good cross-protection, averaging 81% against challenge with five variant isolates from the US having amino acid identity values ranging from 62 to 69% to Mass and from 68 to 83% to Ark, respectively. In contrast, the H120 vaccine strain induced low levels of protection, ranging from 25 to 58% against variant field isolates from Israel with amino acid identity values from 65 to 67%.